Odyssey Therapeutics Reports Third-Quarter 2026 Results and Clinical Update
The company said additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof.
The company said additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof.